Ascendis Pharma (ASND) Stock Forecast & Price Target

Ascendis Pharma is supported by a diversified rare-disease franchise, with YORVIPATH driving current growth, SKYTROFA providing an established revenue base, and YUVIWEL adding a third commercial engine that entered the U.S. market in Apr. 2026 and exceeded 220 unique patient enrollments through July 31. The company’s fundamentals are strengthened by strong payer access, with YUVIWEL reimbursement approval above 65% and YORVIPATH scaling to €252 million in 2Q26, while non-IFRS operating margin expanded to 27% from 22% in 1Q26. Its outlook is further reinforced by a lean cost structure, broad patent protection through 2040–2042, and a known royalty settlement that removes litigation uncertainty while allowing management to focus on execution and pipeline expansion.

Ascendis Pharma is weighed down by slow conversion of enrollments into reimbursed starts, realized net pricing that lands well below gross WAC, and reimbursement approvals that remain stalled below the current >65% threshold, all of which constrain near-term revenue quality and operating leverage. Its YUVIWEL opportunity is also fundamentally uncertain because only two years of trial data are available, final adult height and long-term safety remain open, and no direct head-to-head trial against VOXZOGO has been run, leaving payer and regulator skepticism unresolved. Competitive and execution risks are substantial, with VOXZOGO already established, BMN 333 and other competitors advancing, and U.S. supply, patent, and import issues creating additional downside to adoption and durability across Ascendis’ franchises.